Martel F, Martins M J, Azevedo I
Department of Biochemistry, Faculty of Medicine, Porto, Portugal.
Naunyn Schmiedebergs Arch Pharmacol. 1996 Aug-Sep;354(3):305-11. doi: 10.1007/BF00171061.
1-Methyl-4-phenylpyridinium (MPP+), the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), is efficiently taken up and accumulated by rat hepatocytes. However, the nature of the mechanism(s) involved in the hepatic uptake of MPP+ remains partially unknown. The aim of the present study was to further characterize the hepatic uptake of 3H-MPP+, namely by investigating the interactions of catecholamines (which are also efficiently taken up by rat hepatocytes) with MPP+ transport. The accumulation of 3H-MPP+ in isolated rat hepatocytes occurred through saturable and non-saturable mechanisms. The kinetics of the saturable component of 3H-MPP+ uptake was as follows: Vmax = 181.3 +/- 11.1 pmol mg protein-1 min-1 and Km = 47.1 microM (27.9, 66.3) (n = 5). The diffusion constant (in ml mg protein-1 min-1) for the non-saturable uptake of 3H-MPP+ was 0.00068 (0.00052, 0.00083) (n = 5). From the analysis of the time course of 3H-MPP+ accumulation at a substrate concentration of 100 nM 3H-MPP+, it was found that the rate constant of inward transport of 3H-MPP+ into hepatocytes (k(in)) was 15.7 +/- 3.8 microliters mg protein-1 min-1, the rate constant of outward transport of 3H-MPP+ from hepatocytes (kout) was 0.077 +/- 0.023 min-1 and the equilibrium accumulation (Amax) of 3H-MPP+ was 20.2 +/- 2.0 pmol mg protein-1 (n = 36). Decynium22 (1,1'-diethyl-2,2'-cyanide; 1 microM) significantly reduced kin to 6.1 +/- 1.8 microliters mg protein-1 min-1 (P < 0.05) and the equilibrium accumulation (Amax) of 3H-MPP+ to 9.6 +/- 1.3 pmol mg protein-1 (P < 0.005) (n = 36). 3H-MPP+ accumulation (in cells incubated with 200 nM 3H-MPP+) was sensitive to (-)-adrenaline, (-)-isoprenaline, (-)-dopamine, (+/-)-adrenaline and (-)-noradrenaline. The most potent catecholamine in inhibiting 3H-MPP+ uptake was (-)-adrenaline, with an IC50 of 99 (22, 449) microM (n = 6). (-)-Adrenaline competitively inhibited 3H-MPP+ uptake, as it significantly increased the Km value of 3H-MPP+ uptake (to 125.4 microM (63.6; 187.1); P < 0.02; n = 3) but did not change the Vmax value. The cyanine-derivatives decynium22 and cyanine863 (1-ethyl-2-([1,4-dimethyl-2-phenyl-6-pyrimidinylidene] methyl)quinolinium), which inhibit uptake2 as well as the apical type of the renal transporter for organic cations, potently inhibited 3H-MPP+ uptake with IC50's of 1.4 (0.4-5.3) (n = 6) and 6.5 (2.6-16) (n = 4) microM, respectively. Under conditions of monoamine oxidase (MAO) and catechol-O-methyl transferase (COMT) inhibition (with either pargyline (500 microM) + Ro01-2812 (3,5-dinitropyrocatechol; 2 microM) or pargyline (500 microM) + U-0521 (3,4-dihidroxy-2-methyl-propiophenone; 12 microM)), (-)-adrenaline (up to 1 mM) had no inhibitory effect on the uptake of 3H-MPP+. Moreover, the uptake of 3H-MPP+ in the presence of pargyline + Ro 01-2812 was significantly lower (66.9 +/- 30.4%; P < 0.05; n = 4) than in the absence of these compounds. Therefore, the effect of these MAO and COMT inhibitors on 3H-MPP+ uptake was examined. Interestingly enough, pargyline, Ro 01-2812 and U-0521 were found to inhibit the uptake of 3H-MPP+ (in cells incubated with 200 nM 3H-MPP+): 500 microM pargyline, 2 microM Ro 01-2812 and 100 microM U-0521 decreased the accumulation of 3H-MPP+ to 38.1 +/- 6.8 (n = 5), 60.5 +/- 10.1 (n = 7) and 71.3 +/- 14.5 (n = 7) % of control, respectively. It is concluded that 3H-MPP+ is efficiently taken up by rat hepatocytes by a carrier-mediated mechanism sensitive to catecholamines, decynium22 and cyanane863, and to the enzyme inhibitors pargyline, Ro 01-2812 and U-0521.
1-甲基-4-苯基吡啶鎓(MPP+)是1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)的神经毒性代谢产物,能被大鼠肝细胞有效摄取并蓄积。然而,MPP+肝脏摄取所涉及机制的本质仍部分未知。本研究的目的是进一步表征3H-MPP+的肝脏摄取,即通过研究儿茶酚胺(其也能被大鼠肝细胞有效摄取)与MPP+转运的相互作用。3H-MPP+在分离的大鼠肝细胞中的蓄积通过可饱和和不可饱和机制发生。3H-MPP+摄取可饱和成分的动力学如下:Vmax = 181.3±11.1 pmol mg蛋白-1 min-1,Km = 47.1 μM(27.9, 66.3)(n = 5)。3H-MPP+不可饱和摄取的扩散常数(单位为ml mg蛋白-1 min-1)为0.00068(0.00052, 0.00083)(n = 5)。通过分析在底物浓度为100 nM 3H-MPP+时3H-MPP+蓄积的时间进程,发现3H-MPP+进入肝细胞的内向转运速率常数(k(in))为15.7±3.8 μl mg蛋白-1 min-1,3H-MPP+从肝细胞的外向转运速率常数(kout)为0.077±0.023 min-1,3H-MPP+的平衡蓄积量(Amax)为20.2±2.0 pmol mg蛋白-1(n = 36)。癸氰碘铵(1,1'-二乙基-2,2'-氰化物;1 μM)显著降低k(in)至6.1±1.8 μl mg蛋白-1 min-1(P < 0.05),并使3H-MPP+的平衡蓄积量(Amax)降至9.6±1.3 pmol mg蛋白-1(P < 0.005)(n = 36)。3H-MPP+蓄积(在与200 nM 3H-MPP+孵育的细胞中)对(-)-肾上腺素、(-)-异丙肾上腺素、(-)-多巴胺、(±)-肾上腺素和(-)-去甲肾上腺素敏感。抑制3H-MPP+摄取最有效的儿茶酚胺是(-)-肾上腺素,IC50为99(22, 449)μM(n = 6)。(-)-肾上腺素竞争性抑制3H-MPP+摄取,因为它显著增加了3H-MPP+摄取的Km值(至125.4 μM(63.6;187.1);P < 0.02;n = 3),但未改变Vmax值。抑制摄取2以及肾有机阳离子转运体顶端类型的花青衍生物癸氰碘铵和花青863(1-乙基-2-([1,4-二甲基-2-苯基-6-嘧啶亚基]甲基)喹啉鎓)分别以1.4(0.4 - 5.3)(n = 6)和6.5(2.6 - 16)(n = 4)μM的IC50有效抑制3H-MPP+摄取。在单胺氧化酶(MAO)和儿茶酚-O-甲基转移酶(COMT)抑制条件下(用优降宁(500 μM)+ Ro01-2812(3,5-二硝基邻苯二酚;2 μM)或优降宁(500 μM)+ U-0521(3,4-二羟基-2-甲基苯丙酮;12 μM)),(-)-肾上腺素(高达1 mM)对3H-MPP+摄取无抑制作用。此外,在存在优降宁+ Ro 01-2812的情况下,3H-MPP+的摄取显著低于(66.9±30.4%;P < 0.05;n = 4)不存在这些化合物时的情况。因此,研究了这些MAO和COMT抑制剂对3H-MPP+摄取的影响。有趣的是,发现优降宁、Ro 01-2812和U-0521抑制3H-MPP+摄取(在与200 nM 3H-MPP+孵育的细胞中):500 μM优降宁、2 μM Ro 01-2812和100 μM U-0521分别将3H-MPP+的蓄积量降至对照的38.1±6.8(n = 5)、60.5±10.1(n = 7)和71.3±14.5(n = 7)%。结论是,3H-MPP+通过一种对儿茶酚胺、癸氰碘铵和花青863以及酶抑制剂优降宁、Ro 01-2812和U-0521敏感的载体介导机制被大鼠肝细胞有效摄取。